Cargando…

MON-121 Pain Is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes

Background Lipodystrophy is a group of heterogeneous syndromes characterized by selective loss of adipose tissue and metabolic abnormalities. The severity of pain and its possible relation to measures of quality of life (OoL) and psychoemotional and metabolic health have never been studied in-depth...

Descripción completa

Detalles Bibliográficos
Autores principales: Eldin, Abdelwahab Jalal, Akinci, Baris, Luo, Yingying, de Freitas, Maria Cristina Foss, Swaidan, Mario, Meral, Rasimcan, Rus, Diana, Hench, Rita, Neidert, Adam, Stratton, Andra, Spino, Cathie, Clauw, Daniel, Oral, Elif A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208033/
http://dx.doi.org/10.1210/jendso/bvaa046.1127
_version_ 1783530745567903744
author Eldin, Abdelwahab Jalal
Akinci, Baris
Luo, Yingying
de Freitas, Maria Cristina Foss
Swaidan, Mario
Meral, Rasimcan
Rus, Diana
Hench, Rita
Neidert, Adam
Stratton, Andra
Spino, Cathie
Clauw, Daniel
Oral, Elif A
author_facet Eldin, Abdelwahab Jalal
Akinci, Baris
Luo, Yingying
de Freitas, Maria Cristina Foss
Swaidan, Mario
Meral, Rasimcan
Rus, Diana
Hench, Rita
Neidert, Adam
Stratton, Andra
Spino, Cathie
Clauw, Daniel
Oral, Elif A
author_sort Eldin, Abdelwahab Jalal
collection PubMed
description Background Lipodystrophy is a group of heterogeneous syndromes characterized by selective loss of adipose tissue and metabolic abnormalities. The severity of pain and its possible relation to measures of quality of life (OoL) and psychoemotional and metabolic health have never been studied in-depth previously. Methods LD-Lync study is an international multi-center study collecting data on the natural history of different lipodystrophy syndromes. We have completed phase 1 of the study where only a single site (University of Michigan) entered data (n = 79 patients, M/F: 16/63, mean age: 46.13 ± 14.60, 56 with familial partial lipodystrophy). In this study, we sought to investigate the relationship of pain perception on QoL, psychoemotional and metabolic aspects of the disease. Brief Pain Inventory (BPI) was used to calculate pain severity (BPI-SS) and pain interference scores (BPI-IS). Results From the 77 who completed the questionnaires, 56 (72.73%) patients reported pain at different levels. Out of the 56, 29 (51.79%) patients had moderate/severe pain (BPI-SS ≥ 4). Patients with moderate/severe pain had “more impaired” QoL scores: physical functioning: 20 (15-50) vs. 80 (45-95), p = 0.002; limitation to physical health: 0 (0-25) vs. 75 (0-100), p = 0.002; energy/fatigue 15 (10-30) vs. 45 (20-60), p = 0.032; emotional well-being: 48 (32-60) vs. 72 (48-84), p = 0.029; social functioning: 33 (20-38) vs. 58 (35-70), p = 0.002; general health: 15 (10-25) vs. 35 (20-55), p = 0.005). Severe depression (PHQ-9 > 14) was more frequently detected among patients with moderate/severe pain (63.2% vs. 36.9%, p = 0.008). PHQ-9 score measuring depression was positively correlated with BPI-SS (r = 0.53, p < 0.001), and BPI-IS (r = 0.63, p < 0.001). Emotional burden score was also higher in patients reporting moderate/severe pain (4.0 (2.6-5.0) vs. 2.7 (1.6-3.3), p = 0.015). BPI-SS/BPI-IS scores correlated positively with disease distress (r = 0.33, p < 0.001, and r = 0.31, p = 0.010) and GAD7 scores measuring anxiety (r = 0.52, p < 0.001, and r = 0.50, p < 0.001). Anxiety (GAD7 > 10) was more prevalent among patients with moderate/severe pain (58.6% vs. 23.4%, p = 0.002). The presence of diabetes was associated with higher BPI-SS scores: 3.50 (1.50-5.00) vs. 0 (0-3.25), p = 0.030). Also, patients with HbA1c > 6.5% exhibited higher BPI-SS scores than those with an HbA1c less than 6.5%: 3.38 (1.38-5.00) vs. 1.25 (0-3.50), p = 0.030). Conclusion Our study reveals a high frequency of pain perception among patients with different types of lipodystrophy. Pain severity contributes to worsening in QoL, affects physical and emotional function, and relates to psychoemotional state in patients with lipodystrophy. In addition, the presence of diabetes and higher HbA1c may potentially modulate pain in patients with lipodystrophy. Further work is needed to elucidate the pathways that regulate pain in these patients and to address it effectively.
format Online
Article
Text
id pubmed-7208033
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72080332020-05-13 MON-121 Pain Is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes Eldin, Abdelwahab Jalal Akinci, Baris Luo, Yingying de Freitas, Maria Cristina Foss Swaidan, Mario Meral, Rasimcan Rus, Diana Hench, Rita Neidert, Adam Stratton, Andra Spino, Cathie Clauw, Daniel Oral, Elif A J Endocr Soc Healthcare Delivery and Education Background Lipodystrophy is a group of heterogeneous syndromes characterized by selective loss of adipose tissue and metabolic abnormalities. The severity of pain and its possible relation to measures of quality of life (OoL) and psychoemotional and metabolic health have never been studied in-depth previously. Methods LD-Lync study is an international multi-center study collecting data on the natural history of different lipodystrophy syndromes. We have completed phase 1 of the study where only a single site (University of Michigan) entered data (n = 79 patients, M/F: 16/63, mean age: 46.13 ± 14.60, 56 with familial partial lipodystrophy). In this study, we sought to investigate the relationship of pain perception on QoL, psychoemotional and metabolic aspects of the disease. Brief Pain Inventory (BPI) was used to calculate pain severity (BPI-SS) and pain interference scores (BPI-IS). Results From the 77 who completed the questionnaires, 56 (72.73%) patients reported pain at different levels. Out of the 56, 29 (51.79%) patients had moderate/severe pain (BPI-SS ≥ 4). Patients with moderate/severe pain had “more impaired” QoL scores: physical functioning: 20 (15-50) vs. 80 (45-95), p = 0.002; limitation to physical health: 0 (0-25) vs. 75 (0-100), p = 0.002; energy/fatigue 15 (10-30) vs. 45 (20-60), p = 0.032; emotional well-being: 48 (32-60) vs. 72 (48-84), p = 0.029; social functioning: 33 (20-38) vs. 58 (35-70), p = 0.002; general health: 15 (10-25) vs. 35 (20-55), p = 0.005). Severe depression (PHQ-9 > 14) was more frequently detected among patients with moderate/severe pain (63.2% vs. 36.9%, p = 0.008). PHQ-9 score measuring depression was positively correlated with BPI-SS (r = 0.53, p < 0.001), and BPI-IS (r = 0.63, p < 0.001). Emotional burden score was also higher in patients reporting moderate/severe pain (4.0 (2.6-5.0) vs. 2.7 (1.6-3.3), p = 0.015). BPI-SS/BPI-IS scores correlated positively with disease distress (r = 0.33, p < 0.001, and r = 0.31, p = 0.010) and GAD7 scores measuring anxiety (r = 0.52, p < 0.001, and r = 0.50, p < 0.001). Anxiety (GAD7 > 10) was more prevalent among patients with moderate/severe pain (58.6% vs. 23.4%, p = 0.002). The presence of diabetes was associated with higher BPI-SS scores: 3.50 (1.50-5.00) vs. 0 (0-3.25), p = 0.030). Also, patients with HbA1c > 6.5% exhibited higher BPI-SS scores than those with an HbA1c less than 6.5%: 3.38 (1.38-5.00) vs. 1.25 (0-3.50), p = 0.030). Conclusion Our study reveals a high frequency of pain perception among patients with different types of lipodystrophy. Pain severity contributes to worsening in QoL, affects physical and emotional function, and relates to psychoemotional state in patients with lipodystrophy. In addition, the presence of diabetes and higher HbA1c may potentially modulate pain in patients with lipodystrophy. Further work is needed to elucidate the pathways that regulate pain in these patients and to address it effectively. Oxford University Press 2020-05-08 /pmc/articles/PMC7208033/ http://dx.doi.org/10.1210/jendso/bvaa046.1127 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Healthcare Delivery and Education
Eldin, Abdelwahab Jalal
Akinci, Baris
Luo, Yingying
de Freitas, Maria Cristina Foss
Swaidan, Mario
Meral, Rasimcan
Rus, Diana
Hench, Rita
Neidert, Adam
Stratton, Andra
Spino, Cathie
Clauw, Daniel
Oral, Elif A
MON-121 Pain Is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes
title MON-121 Pain Is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes
title_full MON-121 Pain Is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes
title_fullStr MON-121 Pain Is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes
title_full_unstemmed MON-121 Pain Is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes
title_short MON-121 Pain Is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes
title_sort mon-121 pain is a major driver of quality of life and psychoemotional health in lipodystrophy syndromes
topic Healthcare Delivery and Education
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208033/
http://dx.doi.org/10.1210/jendso/bvaa046.1127
work_keys_str_mv AT eldinabdelwahabjalal mon121painisamajordriverofqualityoflifeandpsychoemotionalhealthinlipodystrophysyndromes
AT akincibaris mon121painisamajordriverofqualityoflifeandpsychoemotionalhealthinlipodystrophysyndromes
AT luoyingying mon121painisamajordriverofqualityoflifeandpsychoemotionalhealthinlipodystrophysyndromes
AT defreitasmariacristinafoss mon121painisamajordriverofqualityoflifeandpsychoemotionalhealthinlipodystrophysyndromes
AT swaidanmario mon121painisamajordriverofqualityoflifeandpsychoemotionalhealthinlipodystrophysyndromes
AT meralrasimcan mon121painisamajordriverofqualityoflifeandpsychoemotionalhealthinlipodystrophysyndromes
AT rusdiana mon121painisamajordriverofqualityoflifeandpsychoemotionalhealthinlipodystrophysyndromes
AT henchrita mon121painisamajordriverofqualityoflifeandpsychoemotionalhealthinlipodystrophysyndromes
AT neidertadam mon121painisamajordriverofqualityoflifeandpsychoemotionalhealthinlipodystrophysyndromes
AT strattonandra mon121painisamajordriverofqualityoflifeandpsychoemotionalhealthinlipodystrophysyndromes
AT spinocathie mon121painisamajordriverofqualityoflifeandpsychoemotionalhealthinlipodystrophysyndromes
AT clauwdaniel mon121painisamajordriverofqualityoflifeandpsychoemotionalhealthinlipodystrophysyndromes
AT oralelifa mon121painisamajordriverofqualityoflifeandpsychoemotionalhealthinlipodystrophysyndromes